AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37689244 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05231023
Number of subjects: 442
Study 37689244 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve FGF21 and PF-05231023
Number of subjects: 442
Study 37689323 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS) on left dorsolateral prefrontal cortex (l-DLPFC), n=34
Number of subjects: 102
Study 37689323 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS) on primary motor cortex (M1), n=34
Number of subjects: 102
Study 37689323 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS) on M1, n=34
Number of subjects: 102
Study 37689323 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (s-tDCS) on l-DLPFC, n=17
Number of subjects: 102
Study 37689323 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (s-tDCS) on M1, n=17
Number of subjects: 102
Study 37689574 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 288
Study 37689622 — intervention group
Group type: EXPERIMENTAL
Intervention: Painted playgrounds intervention
Number of subjects: 51
Study 37689622 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 51
Study 37689733 — intervention group
Group type: EXPERIMENTAL
Intervention: Claudin 18.2 CAR T cell therapy
Number of subjects: 2
Study 37689749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose carboplatin-thiotepa-cyclophosphamide
Number of subjects: 122
Study 37689749 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (ddAC only or ddAC-capecitabine/decetaxel [CD] or ddAC-carboplatin/paclitaxel [CP])
Number of subjects: 122
Study 37689749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 122
Study 37689749 — intervention group
Group type: COMPARATOR
Intervention: ddAC/ddAC-CD
Number of subjects: 122
Study 37689749 — intervention group
Group type: COMPARATOR
Intervention: ddAC-CP
Number of subjects: 122
Study 37689749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alkylating chemotherapy
Number of subjects: 122
Study 37689822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing panel for 26 drugs
Number of subjects: 2612
Study 37689822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing panel for aripiprazole and serotonin or serotonin-norepinephrine reuptake inhibitors
Number of subjects: 2612
Study 37689979 — intervention group
Group type: EXPERIMENTAL
Intervention: HER3-DXd 5.6 mg/kg once every 3 weeks
Number of subjects: 225
Study 37690061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorundrostat 100 mg once daily
Number of subjects: 200
Study 37690061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorundrostat 50 mg once daily
Number of subjects: 200
Study 37690061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorundrostat 12.5 mg once daily
Number of subjects: 200
Study 37690061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 37690061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorundrostat 25 mg twice daily
Number of subjects: 200
Study 37690061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorundrostat 12.5 mg twice daily
Number of subjects: 200
Study 37690061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorundrostat 100 mg once daily (participants without suppressed PRA)
Number of subjects: 200
Study 37690061 — intervention group
Group type: COMPARATOR
Intervention: Lorundrostat 50 mg once daily vs Placebo
Number of subjects: 200
Study 37690061 — intervention group
Group type: COMPARATOR
Intervention: Lorundrostat 100 mg once daily vs Placebo
Number of subjects: 200
Study 37690312 — intervention group
Group type: EXPERIMENTAL
Intervention: d-serine and auditory remediation
Number of subjects: 0
Study 37690312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37690320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib + ET
Number of subjects: 53
Study 37690320 — intervention group
Group type: COMPARATOR
Intervention: ET only
Number of subjects: 53
Study 37690438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer tracking
Number of subjects: 80
Study 37690525 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + Therapeutic Education System-Native Version (TES-NAV)
Number of subjects: 53
Study 37690525 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 53
Study 37690525 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + TES-NAV
Number of subjects: 53
Study 37690525 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 53
Study 37690669 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg twice daily for 5 days)
Number of subjects: 1527
Study 37690669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study 37690669 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 1527
Study 37690784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (40 mg/day)
Number of subjects: 86
Study 37690784 — intervention group
Group type: COMPARATOR
Intervention: Low-dose (20 mg/day)
Number of subjects: 86
Study 37690874 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIKV VLP vaccine in seropositive recipients
Number of subjects: 39
Study 37690874 — intervention group
Group type: COMPARATOR
Intervention: CHIKV VLP vaccine in seronegative recipients
Number of subjects: 39
Study 37690911 — intervention group
Group type: EXPERIMENTAL
Intervention: Double reading by one radiologist plus AI
Number of subjects: 55581
Study 37690911 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reading by AI
Number of subjects: 55581
Study 37690911 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple reading by two radiologists plus AI
Number of subjects: 55581
Study 37690911 — intervention group
Group type: COMPARATOR
Intervention: Double reading by two radiologists
Number of subjects: 55581
Study 37690946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 37690946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37690994 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant rs71630754 (additive model)
Number of subjects: 907
Study 37690994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower expression of ERAP1
Number of subjects: 907
Study 37691028 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tools based on clinical parameters combined with immunological molecular markers
Number of subjects: 551
Study 37691028 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular variables alone
Number of subjects: 551
Study 37691028 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1Ra, IL-17A, CCL19, CX3CL1, TNF
Number of subjects: 551
Study 37691028 — intervention group
Group type: COMPARATOR
Intervention: Screening tools based on clinical parameters
Number of subjects: 551
Study 37691092 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based management system for chronic pain patients with SCS implants
Number of subjects: 82
Study 37691092 — intervention group
Group type: COMPARATOR
Intervention: Monthly online follow-ups
Number of subjects: 82
Study 37691144 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with connective tissue graft (CTG) and individualized supportive peri-implant care (SPC) program
Number of subjects: 16
Study 37691321 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition readiness knowledge
Number of subjects: 512
Study 37691321 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition readiness behaviour
Number of subjects: 512
Study 37691321 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 512
Study 37691321 — intervention group
Group type: EXPERIMENTAL
Intervention: Health self-management and transition readiness perceptions
Number of subjects: 512
Study 37691437 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst Pruritus Numerical Rating Scale (NRS)
Number of subjects: 882
Study 37691437 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Symptom Scale (ADerm-SS)
Number of subjects: 882
Study 37691437 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS)
Number of subjects: 882
Study 37691474 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 1000
Study 37691474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 37691530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 0
Study 37691530 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 0
Study 37691729 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 50 mg
Number of subjects: 1228
Study 37691729 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 100 mg
Number of subjects: 1228
Study 37691729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1228
Study 37691729 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 100 mg (for nonresponders)
Number of subjects: 1228
Study 37691729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) (for responders to PBO induction)
Number of subjects: 1228
Study 37691796 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy (ABCT)
Number of subjects: 140
Study 37691796 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy (active control)
Number of subjects: 140
Study 37691850 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol solution 0.01%
Number of subjects: 13
Study 37691850 — intervention group
Group type: COMPARATOR
Intervention: Placebo - noncaloric berry-flavored solution
Number of subjects: 13
Study 37691865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (RAM) plus Erlotinib (ERL)
Number of subjects: 0
Study 37691865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) plus Erlotinib (ERL)
Number of subjects: 0
Study 37691871 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality navigation-guided localization
Number of subjects: 10
Study 37691885 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by de-escalated radiotherapy of 60 Gy with concurrent cisplatin
Number of subjects: 44
Study 37691885 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by standard-dose radiotherapy of 70 Gy with concurrent cisplatin (for those with stable or progressive disease)
Number of subjects: 44
Study 37692042 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative infection (POI)
Number of subjects: 1460
Study 37692042 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with POI
Number of subjects: 1460
Study 37692042 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of POI on all-cause death
Number of subjects: 1460
Study 37692126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg every 4 weeks for 52 weeks
Number of subjects: 1059
Study 37692126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 37692969 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of nabiximols (up to 113.4 mg THC/105 mg CBD)
Number of subjects: 0
Study 37692969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 37693107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues of people smoking cigarettes (2000 ms)
Number of subjects: 0
Study 37693107 — intervention group
Group type: COMPARATOR
Intervention: Cues of cigarette paraphernalia (2000 ms)
Number of subjects: 0
Study 37693107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues of people smoking cigarettes (2000 ms) for PLWHA
Number of subjects: 0
Study 37693107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues of people smoking cigarettes (1000 ms)
Number of subjects: 0
Study 37693107 — intervention group
Group type: COMPARATOR
Intervention: Cues of cigarette paraphernalia (1000 ms)
Number of subjects: 0
Study 37693199 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial late gadolinium enhancement (LA LGE)
Number of subjects: 1697
Study 37693244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 443
Study 37693269 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with first-line anti-HCV drugs for 24 weeks with ribavirin
Number of subjects: 12
Study 37693269 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with sofosbuvir/velpatasvir/ribavirin for 24 weeks
Number of subjects: 12
Study 37693269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall retreatment with first-line anti-HCV drugs
Number of subjects: 12
Study 37693279 — intervention group
Group type: EXPERIMENTAL
Intervention: Early menarche
Number of subjects: 1126
Study 37693279 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of dysmenorrhea at menarche or several years after it
Number of subjects: 1126
Study 37693279 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical symptoms accompanying menarche and menstrual period pain
Number of subjects: 1126
Study 37693279 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management of dysmenorrhea
Number of subjects: 1126
Study 37693386 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic study of ARFID including saliva sample submission for genotyping.
Number of subjects: 3000
Study 37693386 — intervention group
Group type: EXPERIMENTAL
Intervention: ARFID-GEN study protocol.
Number of subjects: 3000
Study 37693433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment functional connectivity of the seed with the cerebellum, insula, middle occipital gyrus, postcentral gyrus, and precuneus/superior parietal lobule.
Number of subjects: 27
Study 37693433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment functional connectivity with the putamen.
Number of subjects: 27
Study 37693433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- to post-treatment changes in functional connectivity.
Number of subjects: 27
Study 37693433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment functional connectivity between regions involved in attentional salience, self-generated thoughts, and external attention.
Number of subjects: 27
Study 37693433 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and self-report measures of self-focused attention (SFA).
Number of subjects: 27
Study 37693467 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assisted bronchoscopy
Number of subjects: 0
Study 37693467 — intervention group
Group type: COMPARATOR
Intervention: Electromagnetic navigational bronchoscopy
Number of subjects: 0
Study 37693502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclass 1 (patients with septic shock)
Number of subjects: 98
Study 37693502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclass 2 (patients with septic shock)
Number of subjects: 98
Study 37693502 — intervention group
Group type: COMPARATOR
Intervention: Noninfected controls without shock
Number of subjects: 98
Study 37693586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment histidine concentration
Number of subjects: 0
Study 37693586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of glutamate
Number of subjects: 0
Study 37693586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of phenylalanine
Number of subjects: 0
Study 37693586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of tyrosine
Number of subjects: 0
Study 37693586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment concentrations of valine
Number of subjects: 0
Study 37693596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 40
Study 37693596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37693768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Number of subjects: 88
Study 37693768 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Number of subjects: 88
Study 37693914 — intervention group
Group type: EXPERIMENTAL
Intervention: HSG4112
Number of subjects: 0
Study 37693914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37694347 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DXd 5.4 mg/kg
Number of subjects: 152
Study 37694347 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DXd 6.4 mg/kg
Number of subjects: 152
Study 37694399 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic subcision at 100 Hz
Number of subjects: 15
Study 37694399 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic subcision at 50 Hz
Number of subjects: 15
Study 37694449 — intervention group
Group type: EXPERIMENTAL
Intervention: Garetosmab (10 mg/kg, intravenous, every 4 weeks)
Number of subjects: 44
Study 37694449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous, every 4 weeks)
Number of subjects: 44
Study 37694854 — intervention group
Group type: EXPERIMENTAL
Intervention: MNK inhibitor eFT508
Number of subjects: 0
Study 37694854 — intervention group
Group type: EXPERIMENTAL
Intervention: MNK inhibitors (eFT508, CGP57380, cercosporamide)
Number of subjects: 0
Study 37694854 — intervention group
Group type: EXPERIMENTAL
Intervention: siRNA to deplete MNK
Number of subjects: 0
Study 37695272 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation using the serious game 'MoveHero'
Number of subjects: 22
Study 37695272 — intervention group
Group type: COMPARATOR
Intervention: Non-ASD individuals (control group)
Number of subjects: 22
Study 37695331 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37695378 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib plus lenalidomide and dexamethasone (IRd)
Number of subjects: 295
Study 37695506 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA)
Number of subjects: 296
Study 37695585 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-tailored online intervention (chatbot delivering tailored health promotion messages via WhatsApp, 4 sessions every 2 weeks)
Number of subjects: 396
Study 37695585 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-tailored online intervention
Number of subjects: 396
Study 37695585 — intervention group
Group type: COMPARATOR
Intervention: Standard non-SOC-tailored online intervention (chatbot delivering general SIV information via WhatsApp, 4 sessions every 2 weeks)
Number of subjects: 396
Study 37695585 — intervention group
Group type: COMPARATOR
Intervention: Standard non-SOC-tailored online intervention
Number of subjects: 396
Study 37695586 — intervention group
Group type: EXPERIMENTAL
Intervention: GOC video intervention delivered by palliative care educators (PCEs) facilitating GOC conversations using video decision aids.
Number of subjects: 10802
Study 37695586 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 10802
Study 37695586 — intervention group
Group type: EXPERIMENTAL
Intervention: GOC video intervention for Black or African American individuals.
Number of subjects: 10802
Study 37695586 — intervention group
Group type: EXPERIMENTAL
Intervention: GOC video intervention for Hispanic or Latino individuals.
Number of subjects: 10802
Study 37695586 — intervention group
Group type: EXPERIMENTAL
Intervention: GOC video intervention for non-English speakers.
Number of subjects: 10802
Study 37695586 — intervention group
Group type: EXPERIMENTAL
Intervention: GOC video intervention for people living with Alzheimer disease and related dementias.
Number of subjects: 10802
Study 37695621 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out automatic mammography referral
Number of subjects: 883
Study 37695621 — intervention group
Group type: COMPARATOR
Intervention: Opt-in automated telephone call with option for mammography referral
Number of subjects: 883
Study 37695623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 382
Study 37695623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 37695623 — intervention group
Group type: COMPARATOR
Intervention: Ravulizumab vs Placebo
Number of subjects: 382
Study 37695655 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc Tracker app
Number of subjects: 122
Study 37695655 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc Tracker app with cardiologic on-call service
Number of subjects: 122
Study 37695655 — intervention group
Group type: COMPARATOR
Intervention: Routine ECG workflow
Number of subjects: 122
Study 37695657 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise group
Number of subjects: 69
Study 37695657 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame group (Nintendo Wii)
Number of subjects: 69
Study 37695657 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game group (Becure Balance System)
Number of subjects: 69
Study 37695740 — intervention group
Group type: EXPERIMENTAL
Intervention: Better orienting ability and more state rumination
Number of subjects: 92
Study 37695740 — intervention group
Group type: EXPERIMENTAL
Intervention: Better orienting efficiency and lower negative interpretation bias
Number of subjects: 92
Study 37695740 — intervention group
Group type: EXPERIMENTAL
Intervention: State rumination
Number of subjects: 92
Study 37695752 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-grade device (Ax6)
Number of subjects: 0
Study 37695752 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial device (DorsaVi ViMove2)
Number of subjects: 0
Study 37695752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-end multimodal system (DANU Sports System)
Number of subjects: 0
Study 37695822 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Intervention
Number of subjects: 0
Study 37695822 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 37695982 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 37695982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0